Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma

Cancer

Volumn 78, Issue 3 SUPPL., 1996, Pages 674-679

  Robertson, John M ^a,b   Shewach, Donna S ^a   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

fluoropyrimidines; gemcitabine; pancreatic cancer; preclinical studies; radiosensitizers; thymidine analogs

Indexed keywords

FLOXURIDINE; FLUOROURACIL; GEMCITABINE; THYMIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; HUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; RADIOSENSITIZATION; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; BROMODEOXYURIDINE; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FLOXURIDINE; FLUOROURACIL; IDOXURIDINE; PANCREATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED;

EID: 0029995764     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960801)78:3<674::AID-CNCR48>3.0.CO;2-T     Document Type: Review

References (48)

1. Tepper J, Nardi G, Suit H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Cancer 1976;37:1519-24.
2. Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RES, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 1990;66:56-61.
3. Whittington R, Bryer MP, Hailer DG, Solin LG, Rosato EF. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1991;21:1137-43.
4. Kaiser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903.
5. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987;59:2006-10.
6. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitmeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-FU. Cancer 1981;48:1705-10.
7. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751-5.
8. Klaassen DJ, MacIntyre IM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - An Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3:373-8.
9. Whittington R, Dobelbower RR, Mohiuddin M, Rosato FE, Weiss SM. Radiotherapy of unresectable pancreatic carcinoma: a six year experience with 104 patients, Int J Radiat Oncol Biol Phys 1981;7:1639-44.
10. Maybaum J, Ullman B, Mandel HG, Day JL, Sadee W. Regulation of RNA- and DNA-directed actions of 5-fluoropyrimidines in mouse T-lymphoma (S-49) cells. Cancer Res 1980;40:4209-15.
11. Washtien WL. Comparison of 5-fluorouracil metabolism in two human gastrointestinal tumor cell lines. Cancer Res 1984;44:909-14.
12. Ensminger WD, Rosowsky A, Raso V, Levin DC, Glode M, Come S, et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res 1978;38:3784-92.
13. Lawrence TS, Maybaum J. Fluoropyrimidines as radiation sensitizers. Semin Radiat Oncol 1993;3:20-8.
14. Moran RG. Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase. Cancer 1980; 63:1008-12.
15. Ingraham H, Dickey L, Goulian M. DNA fragmentation and cytotoxicity from increased cellular deoxyuridylate. Biochemistry 1986;25:3225-30.
16. Carman CE, Lawrence TS, Shewach DS, Tang H-Y, Maybaum J. Resistance to fluorodeoxyuridine-induced DNA damage and cytotoxicity correlates with an elevation of dUTPase activity and failure to accumulate dUTP. Cancer Res 1993;53:5219-24.
17. Carman CE, Radany EH, Parsels LA, Davis MA, Lawrence TS, Maybaum J. Induction of resistance to fluorodeoxyuridine cytotoxicity and DNA damage in human tumor cells by expression of Escherichia coli deoxyuridinetriphosphatase. Cancer Res 1994;54:2296-8.
18. Byfield JE, Calabro-Jones P, Klisak LL, Fulhanian F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and x rays, Int J Radiat Oncol Biol Phys 1982;8:1923-33.
19. Lawrence TS, Heimburger DK, Shewach DS. The effects of leucovorin and dipyridamole on fluoropyrimidine-induced radiosensitization. Int J Radiat Oncol Biol Phys 1991;20:377-81.
20. Lawrence TS, Davis MA, Maybaum J. Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects. Int J Radiat Oncol Biol Phys 1994;29:519-23.
21. Bruso CE, Shewach DS, Lawrence TS, Fluorodeoxyuridine induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells. Int J Radiat Oncol Biol Phys 1990;19:1411-7.
22. Heimburger DK, Shewach DS, Lawrence TS. The effect of fluorodeoxyuridine on sublethal damage repair in human colon cancer cells, Int J Radiat Oncol Biol Phys 1991;21:983-7.
23. Davis MA, Tang HY, Maybaum J, Lawrence TS. Cell cycle dependence of fluorodeoxyuridine-mediated radiosensitization. Proceedings of the 41st Annual Meeting of the Radiation Research Society P1; 1994:7-293.
24. Kinsella TJ, Mitchell JB, Russo A, Morstyn G, Glatstein E. The use of halogenated thymidine analogs as clinical radiosensitizers: rationale, current status, and future prospects: non-hypoxic cell sensitizers. Int J Radiat Oncol Biol Phys 1984;10:1399-1406.
25. Kinsella TJ, Russo A, Mitchell JB, Rowland J, Jenkins J, Schwade J, et al. A phase I study of intermittent intravenous bromodeoxyuridine (BUDR) with conventional fractionated irradiation. Int J Radiat Oncol Biol Phys 1984; 10:69-76.
26. Hegarty TJ, Thornton AF, Diaz RF, Chandler WF, Ensminger WD, Junck L, et al. Intra-arterial bromodeoxyuridine radiosensitization of malignant gliomas. Int J Radiat Oncol Biol Phys 1990; 19:421-8.
27. Phillips TL, Leven VA, Ahan DK, Gutin PH, Davis RL, Wilson CB, et al. Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase II study. Int J Radiat Oncol Biol Phys 1991;21:709-14.
28. Sondak VK, Lawrence TS, Ensminger WD, Chang AE. Preoperative IUdR and radiation for soft tissue sarcomas: preliminary results and normal tissue IUdR incorporation data [abstract]. Proc Am Soc Clin Oncol 1990;9:317.
29. Robertson JM, Sondak VK, Weiss SA, Sussman JJ, Chang AE, Lawrence TS. Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys 1995;31:87-92.
30. Lawrence TS, Davis MA, McKeever PE, Maybaum J, Stetson PL, Normolle DP, et al. Fluorodeoxyuridine-mediated modulation of iododeoxyuridine incorporation and radiosensitization in human colon cancer cells in vitro and in vivo. Cancer Res 1991;51:3900-5.
31. Greene RF, Collins JM. Effects of leucovorin on idoxuridine cytotoxicity and DNA incorporation. Cancer Res 1990; 50:6652-6.
32. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9:491-8.
33. Poplin EA, Corbett T, Flaherty L, Tarasoff P, Redman BG, Valdivieso M, et al. Difluorodeoxycytidine (dFdC) - gemcitabine: a phase I study. Invest New Drugs 1992; 10(1):65-70.
34. Lund B, Kristjansen PEG, Hansen HH. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 1993; 19:45-55.
35. Moore M, Andersen I, Burns H, Tarassof P, Green M, Casper E, et al. A randomized trial of gemcitabine (GEM) versus 5FU as first-line therapy in advanced pancreatic cancer [abstract no. 473]. Proc Am Soc Clin Oncol 1995; 14:199.
36. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′deoxycytidine). Cancer Res 1990;50:4417-22.
37. Merriman RL, Schultz RM, Hertel LW, Houghton PJ, Houghton JA, Grindey GB. Evaluation of the antitumor activity of gemcitabine against human carcinoma xenografts [abstract]. Proc Am Assoc Cancer Res 1994;35:448.
38. Kaye SB. Gemcitabine: current status of phase I and II trials [editorial]. J Clin Oncol 1994; 12:1527-31.
39. Pollera CF, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from phase I study. Ann Oncol 1994;5:182-4.
40. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994;54:3218-23.
41. Heinemann V, Xu Y-Z, Chubb S, Sen A, Hertel LW, Grindey GB, et al. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate: a mechanism of self-potentiation. Cancer Res 1992;52:533-9.
42. Lawrence TS, Chang EY, Davis MA, Hertel L, Shewach DS. Gemcitabine radiosensitizes human pancreas cancer cells. AACR 1994;35:3855.(P).
43. Hughes LL, Luengas J, Rich TA, Murray D. Radiosensitization of cultured human colon adenocarcinoina cells by 5-fluorouracil: effects on cell survival, DNA repair, and cell recovery. Int J Radiat Oncol Biol Phys 1992;23:983-91.
44. Rich TA, Lokich JJ, Chaffey JT. A pilot study of protracted venous infusion of 5-fluorouracil and concomitant radiation therapy. J Clin Oncol 1985;3:402-6.
45. Kriss JP, Revesz L. The distribution and fate of bromodeoxyuridine in the mouse and rat. Cancer Res 1962;22:254-65.
46. Kriss JP, Maruyama Y, Tung LA, Bond SB, Revesz L. The fate of 5-bromodeoxyuridine, 5-bromodeoxycytidine and 5-iododeoxycytidine in man. Cancer Res 1963;23:260-8.
47. Bagshaw MA, Doggett RLS, Smith KC, Kaplan HS, Nelsen TS. Intraarterial 5-bromodeoxyuridine and X-ray therapy. Am J Roent Radiat Ther Nucl Med 1967;99:886-94.
48. Lawrence TS, Davis MA, Stetson PL, Maybaum J, Ensminger WD. Kinetics of bromodeoxyuridine elimination from human colon cancer cells in vitro and in vivo. Cancer Res 1994;54:2964-8.